FLT3-MUTATED ACUTE MYELOID LEUKEMIA
Clinical trials for FLT3-MUTATED ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new FLT3-MUTATED ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for FLT3-MUTATED ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy holds promise for kids with rare leukemia
Disease control OngoingThis study tests whether adding the drug midostaurin to standard chemotherapy can safely control a rare, aggressive leukemia (FLT3-mutated AML) in children. About 22 children will receive the drug twice daily alongside chemo, then continue midostaurin alone for 12 more cycles. Th…
Matched conditions: FLT3-MUTATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New triple therapy targets tough leukemia in older patients
Disease control OngoingThis study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with a fast-growing form of acute myeloid leukemia (AML) that has a specific gene change (FLT3 mutation). Participants are older or have other health issues that pr…
Matched conditions: FLT3-MUTATED ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC